Armata Pharmaceuticals, Inc.

• 8-KPositiveContract / partnership

  Filed Sep 23

  First Phase 3-specific DoW funding backs AP-SA02’s superiority study in complicated Staphylococcus aureus bacteremia.

• 8-KPositiveClinical / regulatory decision

  Filed Sep 14

  FDA grants AP-SA02 Breakthrough Therapy status after higher, earlier cure rates in S. aureus bloodstream infections, aiming to expedite development and review.

• 10-QQ2 FY2026NegativeBankruptcy / going concern

  Filed Aug 12

  FDA feedback supports AP-SA02’s planned Phase 3 trial, but new borrowing has not resolved its funding gap.

  • Revenue$2.5MYoY +15.7%
  • Net income$74.1Mvs −$16.3M year ago

• 8-KEarnings

  Filed Aug 12

  AP-SA02 Phase 3 protocol submitted to FDA ahead of planned H2 2026 start; a noncash Convertible Loan gain drove the swing to profit.

• 8-KPositiveCEO/CFO changeContract / partnership

  Filed Jul 20

  AP-SA02 protocol submission and completed manufacturing engineering runs advance Phase 3 readiness ahead of a planned H2 2026 start

• 8-KCEO/CFO change

  Filed Jul 20

  David House is promoted from SVP of Finance and principal financial officer to CFO.

• 8-KClinical / regulatory decision

  Filed Jul 13

  FDA agrees to AP-SA02’s pediatric plan for complicated S. aureus bacteremia; pediatric studies await adult safety and efficacy data.

• 8-KPositiveContract / partnership

  Filed Jun 23

  Additional non-dilutive DoD funding supports AP-SA02 Phase 3 readiness ahead of a planned H2 2026 superiority study in complicated bacteremia.

• 8-KShareholder vote

  Filed Jun 16

  Shareholders backed annual executive-pay votes and ratified Ernst & Young as FY2026 auditor.

• 10-QQ1 FY2026NegativeBankruptcy / going concern

  Filed May 13

  FDA feedback supports an AP-SA02 Phase 3 bacteremia trial, but funding remains a hurdle despite a new Innoviva loan.

  • Revenue$789.0KYoY +60.7%
  • Net income−$115.3MYoY −1666.1%

• 8-KNegativeEarnings

  Filed May 13

  Innoviva’s secured loan funds AP-SA02 development; noncash convertible-loan revaluation drove the net loss.

• 8-KPositiveClinical / regulatory decision

  Filed May 7

  FDA Fast Track for AP-SA02 in complicated S. aureus bacteremia enables more frequent agency interactions and rolling BLA review.

• 8-KLeadership change

  Filed Apr 27

  Pfizer commercial quality executive Daniel B. Gilmer joins the board; he previously led the U.S. launch of PAXLOVID.

• 8-K

  Filed Apr 2

  June 11 annual meeting set; stockholder proposals and director nominations must comply with Armata’s advance-notice bylaws.

• 10-KFY2025NegativeBankruptcy / going concernImpairment / charge

  Filed Mar 25

  Favorable FDA feedback moved AP-SA02 toward Phase 3, but a going-concern warning puts trial financing in focus.

  • Revenue$4.9MYoY −5.2%
  • Net income−$173.8MYoY −818.8%

• 8-KNegativeEarningsBankruptcy / going concernImpairment / charge

  Filed Mar 25

  Convertible-loan fair-value loss drove Q4’s net loss; Innoviva credit maturities extended to June 2027 amid an auditor’s going-concern warning.

• 8-KPositiveClinical / regulatory decision

  Filed Mar 19

  FDA granted AP-SA02 QIDP status and confirmed Phase 2a data support a planned Phase 3 trial for complicated S. aureus bacteremia.

• 8-KPositiveClinical / regulatory decision

  Filed Feb 23

  FDA grants AP-SA02 QIDP status for complicated bacteremia, making it eligible for longer exclusivity; Armata plans to seek Fast Track.

• 8-KDebt financingGovernance change

  Filed Jan 26

  Innoviva Strategic Opportunities extends credit and warrant terms; FDA approval would end the amended voting agreement early.

• 8-KPositiveClinical / regulatory decision

  Filed Jan 13

  FDA supports advancing AP-SA02 to a Phase 3 superiority trial for complicated S. aureus bacteremia, expected to start in H2 2026.

Coverage: 10-K filings filed since Mar 25, 2026; 10-Q since May 13, 2026; 8-K since Jan 13, 2026.

Request longer coverage